Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Natural Antibiotic Synthesis Mechanisms Uncovered

Scientists have discovered a new protein that likely will advance the search for new natural antibiotics. [NIH] Understanding the molecular mechanisms that trigger the production of antibiotic compounds, especially through the regulation of gene expression, co

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Scientists have discovered a new protein that likely will advance the search for new natural antibiotics. [NIH]

Understanding the molecular mechanisms that trigger the production of antibiotic compounds, especially through the regulation of gene expression, could help scientists advance the search for new natural antimicrobial agents. Now, a group of investigators, led by researchers at Texas A&M AgriLife Research, has discovered a new protein that could prove invaluable as many researchers continue their hunt for new natural products.

The recent findings deal with how proteins regulate gene expression. Scientists have known a great deal about how proteins that control certain gene clusters get their start—referred to as transcription initiation. However, much less is known about transcription elongation where proteins keep gene expression going through “roadblocks” in the DNA sequence.

“The upshot is that our discovery expands the basic knowledge of processive antitermination—a type of genetic regulation—and demonstrates that the mechanism is more widespread among bacteria than previously thought,” explained co-senior study investigator Paul Straight, Ph.D., associate professor in the department of biochemistry and biophysics at Texas A&M AgriLife Research**. “Antibiotic production by bacteria involves complex chemistry that is often encoded in a collection or 'cluster' of many genes. To express these giant gene clusters requires special regulation mechanisms. Understanding these mechanisms could help a great deal in the search for new antibiotics produced by bacteria.”

The findings from this study were published recently in Nature Microbiology in an article entitled “LoaP Is a Broadly Conserved Antiterminator Protein That Regulates Antibiotic Gene Clusters in Bacillus amyloliquefaciens.”

The authors describe two discoveries in their new paper. One is the protein they named LoaP, which stands for long operon-associated protein. The other discovery is that this protein is frequently found next to the gene clusters that are responsible for producing antibiotics. Hence, knowing how LoaP works and its prime location could lead scientists to a shortcut for antibiotic production.

“These long chains of genes raise challenges for the molecular machines that decode DNA,” Dr. Straight noted. “Sometimes the molecular machines hit roadblocks, called terminators, and they stop and fall off the DNA. The LoaP protein is called a processive antiterminator because it helps the machines stay on DNA and move through the roadblock terminators.”

The research team discovered the LoaP protein in Bacillus amyloliquefaciens, a bacterium known to ward off pathogens that attack plant roots in agriculture, aquaculture, and hydroponic production.

“In this study, we analysed the phylogenetic distribution of the large, widespread NusG family of transcription elongation proteins and found that it includes a cohesive outgroup of paralogues (herein coined LoaP), which are often positioned adjacent or within gene clusters for specialized metabolites,” the authors wrote. “We established Bacillus amyloliquefaciens LoaP as a paradigm for this protein subgroup and showed that it regulated the transcriptional readthrough of termination sites located within two different antibiotic biosynthesis operons.”

The researchers noted that while the Earth has an abundant and diverse supply of microbes such as bacteria, many of them with useful biomedical purposes, a modern limitation to antibiotic discovery is the murky understanding of the genetic regulatory mechanisms that oversee their production.

“After nearly a century of searching for bioactive natural products, bacteria still constitute a major target of modern drug discovery,” Dr. Straight said. “The characterization of the biochemical pathways of these molecules remains a bottleneck to their development.”

Dr. Straight concluded that “one of the key restrictions is a shortage of knowledge on the range of genetic mechanisms that can affect them. Therefore, the discovery of new classes of genetic regulatory mechanisms is likely to impact future development of natural products that counter disease.”

** In the current study, Dr. Straight and his graduate assistant Chengxi Zhang of College Station, teamed up with University of Maryland researchers Jonathan R. Goodson, Steven Klupt and Dr. Wade Winkler.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →